study of Cediranib plus Cisplatin plus Capecitabine/S-1 in Japanese gastric cancer patients

Study identifier:D8480C00066

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label, Non-randomized Study, to assess the Safety and Tolerability of Cediranib (AZD2171) in combination with Cisplatin plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients with Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer

Medical condition

gastric cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

Cediranib, Cisplatin, S-1, Capecitabine

Sex

All

Actual Enrollment

14

Study type

Interventional

Age

20 Years +

Date

Study Start Date: 01 Aug 2009
Primary Completion Date: 01 Jan 2010
Study Completion Date: 01 Mar 2011

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria